baber/WOPTO huggingface dataset:
Patent PT-1488627-E (PT)
Title: Method for billing a communications link between communications terminals
Inventor: FOELL UWE
IPC: H04W4/00
Filed: 2003-03-13
Abstract: The method involves the first terminal (KEG) sending a link establishment request via the Internet (INET) to a mobile network node (GW), which identifies a charging computer (GS1) with stored payment data for the terminal, sending a charge request to the computer, checking whether the terminal will accept the charges, sending an associated response to the network node and establishing or terminating the connection (KV) accordingly.
Patent PT-1549735-E (PT)
Title: Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
Inventor: SOUBRIER FABIENNE
IPC: C12N15/74
Filed: 2003-10-14
Abstract: A circular DNA molecule, useful for gene therapy, comprising at least one nucleic acid sequence of interest, characterised in that the region allowing the replication thereof has an origin of replication with a functionality in a host cell that requires the presence of at least one specific protein foreign to said host cell. A method for preparing same, cells incorporating said DNA molecules and uses thereof in gene therapy are also described.
Patent PT-1471059-E (PT)
Title: 2,4,6-tris(dineopentyl 4`-aminobenzalmalonate)-s-triazin, sunscreen compositions containing this compound and its use
Inventor: RICHARD HERVE
IPC: A61K8/89
Filed: 2004-04-09
Abstract: 2,4,6-tris(phenylamino)-s-triazine derivatives (I) are new. 2,4,6-tris(phenylamino)-s-triazine derivatives of formula (I) are new. [Image] R : -(CHR4)n-(CHR5)m-CR1R2R3; R1, R21-8C linear or branched alkyl, or together complete a 5-8C ring, optionally substituted by 1-3 1-4C linear or branched alkyl; R3-R5H or 1-4C linear or branched alkyl; and m, n : 0 or 1. Provided that when n is 1 and R4 is H, then m = 1 and when R1 and R2 form a 5-8C ring, then n+m is not 2. An independent claim is included for a cosmetic or dermatological composition comprising (I) and a adjuvant.
Patent PT-1608414-E (PT)
Title: Improved osteoinductive materials
Inventor: POHL JENS
IPC: A61L27/34
Filed: 2004-03-26
Abstract: The present invention relates to an osteoinductive material comprising a matrix material with morphogenetic protein(s) absorbed on inner or outer surfaces of this matrix material, wherein the osteoinductive material is obtainable by contacting the matrix material and the morphogenetic protein(s) under conditions of pH and ionic concentration to keep the protein stable and dissolved in a solution until dried and thereby allowing that the matrix material becomes evenly coated with the morphogenetic protein(s). <IMAGE>
Patent PT-1651755-E (PT)
Title: Method for immunotherapy of tumors
Inventor: PENNINGER JOSEF
IPC: A61K35/15
Filed: 2004-08-04
Abstract: A method for making dendritic cells reactive to an antigen comprises obtaining a sample of dendritic cells and contacting the cells with the antigen and at least one Toll-like receptor stimulant. Dendritic cells activated by this method provide a means for treating tumors and for creating animal models of autoimmune diseases.
Patent PT-1631264-E (PT)
Title: Immunogenic compositions based on biodegradable microparticles comprising a diphtheria- and a tetanus toxoid
Inventor: KAZZAZ JINA
IPC: A61K9/50
Filed: 2004-06-02
Abstract: Immunogenic compositions comprising microparticles with adsorbed toxoid antigen and/or polysaccharide-containing antigen are disclosed. The immunogenic microparticle compositions comprising (a) polymer microparticles comprising a biodegradable polymer; (b) an antigen adsorbed to the microparticles selected from (i) a toxoid antigen, such as a tetanus toxoid, a diphtheria toxoid, or a combination thereof, and/or (ii) a polysaccharide containing antigen, such as a Hib polysaccharide antigen, a Hib conjugate antigen comprising polysaccharide and polypeptide regions, a meningococcal polysaccharide antigen, a meningococcal conjugate antigen comprising polysaccharide and polypeptide regions, a pneumococcal polysaccharide antigen, and a pneumococcal conjugate antigen comprising poysaccharide and polypeptide regions or a combination thereof; and (c) a pharmaceutically acceptable excipient.; The biodegradable polymer can be, for example, a polymer selected from a poly(alpha-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and a polycyanoacrylate. Also disclosed are methods of immunization against infection by a pathogenic organisms and methods stimulating immune responses, which comprise administering such compositions to host animals. Methods of producing such microparticle compositions are also disclosed which comprise forming a water-in-oil-in-water emulsion that contains water, organic solvent and biodegradable polymer, followed by removal of the organic solvent from the emulsion to form microparticles, after which toxoid and/or polysaccharide containing antigens are adsorbed on the microparticles.
Patent PT-1983871-E (PT)
Title: Apparatus for producing a brew of an aromatic drink
Inventor: RICOTTI MADDALENA
IPC: A47J31/40
Filed: 2007-02-13
Abstract: The apparatus (1) for producing a brew of an aromatic drink comprises a capsule (2) containing the powder of one or more aromatic essences with which to make the brew, able to be associated with a dispensing device (3) having at least a first and a second dispensing path (4, 5) hydraulically separate from one another, and forced positioning (6, 7) means between the capsule (2) and the dispensing device (3).
Patent PT-1981767-E (PT)
Title: Expandable container having lid for providing headspace control of a food can
Inventor: JONGSMA JELMER EELKE
IPC: B65D17/50
Filed: 2007-02-02
Abstract: The invention suggests a peelable cover panel for a lid of peel type which allows a safe sterilization of filled and closed cans in continuous autoclaves (high temperature prevailing there and a resultant high pressure in the can) avoiding risk of breaking, breaking up or detaching said plane (surface oriented) cover panel on or from the seamable annular ring. After the cooling of the can, the lid also has an acceptable appearance. Suggested therefore is a cover panel for sealing to an annular ring to provide a lid to close a can body and allow a thermally treating pasteurization or sterilization process of the closed can in a continuous autoclave. The cover panel (3) having a radially outer ring band (3a) for sealingly affixing to a flat web (6) and a remaining central portion (3b) that is surrounded by the ring band, the control portion being preformed in a bowl-shaped fashion and is for this reason stabilized. The stabilization is such that the bowl-shaped cover panel (3), during an increase in pressure during at least the pasteurization, changes from the preformed bowl-shape as first position (3b) to a second position (3b') that is bowl-shaped axially outwards, and is still able to return to the first position (3b), at least substantially during or after cooling.
Patent PT-2186460-E (PT)
Title: Towelette dispenser
Inventor: SIMKINS NELSON E
IPC: A47K10/38
Filed: 2007-02-27
Abstract: A towelette dispenser (70) is provided with a lid (10). The lid has a central aperture (18) for allowing access to a roll of towelettes maintained within a tub (72) receiving the lid therein. A separation bar (26) bridges the aperture, and provides a rip fence in the form of a thimble (34) that is angled with respect to the lid as a whole. The thimble (34) has fingers (44) and is offset near one edge of the annular opening so that a user may access the rear side thereof to thread an edge of the leading towelette through the thimble without having to remove the lid from the tub. A well (20) is provided in the smaller portion of the aperture and a cap (14) for the lid is provided with a stuffer tab (58) to urge the leading edge of the next towelette into the well when the cap is closed.
Patent PT-2517700-E (PT)
Title: Pharmaceutically acceptable cocrystals of n-[2-(7-methoxy-1-naphthyl]acetamide and methods of their preparation
Inventor: RICHTER JINDRICH
IPC: A61K31/165
Filed: 2011-04-28
Abstract: The present invention relates to novel solid forms of agomelatine (I), specifically novel pharmaceutically acceptable cocrystals thereof, as well as to methods of preparing them. Three pharmaceutically acceptable cocrystals of (I) that have physicochemical properties acceptable for pharmaceutical development were obtained.
Patent PT-751837-E (PT)
Inventor: SVENSSON SIGFRID
IPC: C09D101/00
Filed: 1995-03-23
Abstract: A protective polysaccharide film containing a buffering agent in an amount which is effective for substantially resisting pH changes due to environmental influence; a solution for the application onto a surface to be protected, comprising: a) a polysaccharide dissolved in an aqueous solvent therefore; and b) a buffering agent, said solution being capable of forming a film on said surface which on swelling or dissolution maintains a substantially constant pH due to environmental influence; and a process for protecting a surface from non-desired contamination and to facilitate the removal of such contamination from said surface, comprising the steps: a) applying a solution according to any of claims 7 to 12 on said surface before being subjected to contamination; b) allowing the applied solution to dry with the formation of a solid film on said surface, said film being capable of substantially resisting pH changes due to environmental influence; c) treating said film with a liquid capable of redissolving the film or providing swelling thereof; and d) removing the undesired contamination by completely or partially removing said film from the surface.
Patent PT-813541-E (PT)
Inventor: AGELAND HANS
IPC: C07K1/22
Filed: 1996-03-01
Abstract: A substantially endotoxin-free ApoA or ApoE is produced by recombinant DNA technique, suitably in E. coli. Medicaments and methods for treatment of atherosclerosis or cardiovascular diseases employ ApoA or ApoE purified by a process comprising contacting a first aqueous solution comprising ApoA or ApoE and endotoxins with a matrix comprising an immobilized compound with an end group comprising two or three nitrogen atoms bonded to a carbon atom for attaching the endotoxins to the matrix, and subsequently treating the matrix comprising the immobilized compound with a second aqueous solution comprising a surfactant for releasing the ApoA or ApoE while the endotoxins remain attached to the matrix. Alternatively, the ApoA or ApoE is purified by a process comprising contacting the first aqueous solution comprising ApoA or ApoE and endotoxins with an anion-exchange matrix for attaching the ApoA and ApoE to the matrix, treating the anion-exchange matrix with a second aqueous solution comprising a compound comprising two or three nitrogen atoms bonded to a carbon atom for releasing the endotoxins while the ApoA or ApoE remains attached to the matrix, and then releasing the ApoA or ApoE from the matrix.
Patent PT-817625-E (PT)
Inventor: SHAPIRO STANLEY SEYMOUR
IPC: A61K31/20
Filed: 1996-03-19
Abstract: A method of inducing the repair of photodamage to human skin comprising topically administering a composition containing a multi-selective retinoid which transactivates both of the human RAR- alpha  and RAR- gamma  receptors in combination with a compound which inhibits the binding of said multi-selective compound to the human RAR- alpha  receptor is disclosed.
Patent PT-829540-E (PT)
Inventor: OUELLETTE MARC
IPC: A61P33/02
Filed: 1997-09-12
Abstract: Strains of Leishmania and other macrophage-infecting parasites are provided which express the GM-CSF gene which are useful in treating hosts infected by the parasite and in protecting hosts against disease caused by infection of hosts by parasites. The parasites are reduced in their ability to infect or survive in macrophages and hence are attenuated. At least one gene of the parasite contributing to the virulence thereto may be functionally disabled. The attenuated strains may be used for administration to a host (a) to treat a host infected by Leishmania or (b) to confer protection against disease caused by a virulent Leishmania strain, or as a diagnostic reagent.
Patent PT-944532-E (PT)
Inventor: DOBRESKI DAVID V
IPC: A44B19/16
Filed: 1997-10-22
Abstract: The present invention improves performance of the side and/or fin seals of plastic bags through the use of resins that have a narrow molecular weight distribution or polydispersity. The performance of the side seal and/or fin seal of a plastic bag is improved by using body panels which comprise a first resin, and optionally, a second resin. The first resin is preferably prepared in the presence of a single site catalyst. The first resin has a polydispersity of from about 1 to about 4, a melt index of from about 0.2 to about 20, and a melt flow ratio (I20/I2) of from about 12 to about 35. The use of such first resins results in side and fin seals which are stronger, tougher, and less likely to leak. The second resin is a polymer such as LDPE, LLDPE, or a blend thereof In body panels comprising both a first and a second resin, the first resin may be coextruded with LDPE or LLDPE as a thin layer of the body panel or the first resin may be blended with the LDPE and/or LLDPE.
Patent PT-959961-E (PT)
Inventor: SANDELL TIMO AULIS
IPC: A63B69/00
Filed: 1997-07-15
Abstract: A playing field for playing where the field includes marked sidelines, goal lines and cross-lines at a distance from the goal lines. The playing field includes a total of four goal structures, rather than the conventional two goal structures and thus there are two goal structures located along each goal line spaced from each other along that goal line. The overall soccer field complies with the international regulations governing the dimensions of the field and of the goal structures, however, a new and different game with enhanced excitement is possible with the use of the additional goal structure located along each goal line.
Patent PT-939821-E (PT)
Title: G-beta-gamma regulated phosphatidylinositol-3` kinase
Inventor: BRASELMANN SYLVIA
IPC: C12N9/12
Filed: 1997-06-26
Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode the G protein regulated phosphatidylinositol-3' kinase, a heterodimeric enzyme which produces the intracellular messenger phosphatidylinositol (3, 4,5)-triphosphate in response to activation of trimeric G protein-linked receptors. This novel protein, comprised of a catalytic subunit, p120, and a regulatory subunit, p101, is found in cells of hematopoietic origin and is involved in immune system responses which cause inflammation. The presence of p101 subunit is largely responsible of the dramatic stimulation of kinase activity in the presence of activated trimeric G proteins. The invention encompasses  p101  and  p120  nucleotides, host cells expression systems, p101 and p120 proteins, fusion proteins, polypeptides and peptides, antibodies to these proteins, transgenic animals that express a  p101  or  p120  transgene, or recombinant knock-out cells and animals that do not express the  p101  or  p120  genes, antagonists and agonists of the enzyme, and other compounds that modulate p101 or p120 gene expression or enzyme activity that can be used for diagnosis, drug screening , clinical trial monitoring, and/or treatment of inflammatory disorders.
Patent PT-902018-E (PT)
Title: 2-(arylphenyl)amino-imidazoline derivatives
Inventor: O'YANG COUNDE
IPC: A61P31/04
Filed: 1998-08-26
Abstract: The invention relates to IP receptor antagonists selected from the group of compounds represented by formula <CHEM>  wherein     R<1> is a group represented by formula (A), (B) or (C): <CHEM> and other substituents as defined in the specification, and their pharmaceutically acceptable salts, crystal forms therof and pharmaceutical compositions containing them.
Patent PT-894774-E (PT)
Inventor: SCHMIDT UWE
IPC: C03C17/36
Filed: 1998-07-21
Abstract: The invention concerns a transparent substrate provided with a thin-film stack comprising at least one metallic film with reflective properties in the infrared, under which is disposed a first antireflection coating consisting essentially of one or more metal oxides, and an upper protective metallic film characterized in that the protective metallic film consists of an alloy of Ti, Zr or Hf with Al, Pt or Pd or an AlSi alloy. According to the invention, the second upper antireflection coating includes at least two metal oxide films, one of which is ZnO based and contains 0.1 to 10% by weight of at least one of the elements B, Si, Ga, Sm, Al, Co, Mg, Mn, Fe, Ni and/or Cr and the other is SnO2 or Bi2O3 based, and a final, hard oxide based film.
Patent PT-893048-E (PT)
Inventor: LEGRAND EMMANUEL
IPC: A01D34/416
Filed: 1998-07-22
Abstract: The cutter line for a tool with a rotary head has an inner single or multiple core made from a material selected for its biodegradability and-or photodegradability. The core is covered with a layer (3) of a synthetic material such as polyamide or polyurethane which forms its outer surface. The core, which has a round or stellate cross-section, can be made from a synthetic biodegradable resin, based e.g. on polycaprolactone, on its own or mixed with other synthetic materials. A photodegradable core can be made of rutile or octahedrite titanium oxide or cerium stearate mixed as a charge with a synthetic material, and the coating material is transparent.
Patent PT-984101-E (PT)
Inventor: JUPPO ARI
IPC: D21H17/17
Filed: 1999-08-20
Abstract: The invention relates to a sizing composition usable for the neutral sizing of paper or board, which composition contains a size capable of reacting with cellulose, such as alkyl ketene dimer or alkenyl succinic acid anhydride, and an organic complexing agent. The invention also relates to a process for the manufacture of paper or board.
Patent PT-1115670-E (PT)
Inventor: FINLEY JAMES J
IPC: G02F1/1333
Filed: 1999-09-09
Abstract: Amorphous metal oxide barrier layers of titanium oxide, zirconium oxide and zinc/tin oxide are effective as alkali metal ion barrier layers at thicknesses below 180 Angstroms. The amorphous metal oxide barrier layers are most effective when the density of the layer is equal to or greater than 75% of the crystalline density. The barrier layers prevent migration of alkali metal ions such as sodium ions from glass substrates into a medium e.g. electrolyte of a photochromic cell, liquid material of a liquid crystal display device contacting the glass surface and a photocatalytic coating. The properties of the medium, particularly electroconductive metal oxide coatings, are susceptible to deterioration by the presence of sodium ions migrating from the glass.
Patent SG-43484-G (SG)
Title: Multi-programming data processing system process suspension
IPC: G06F9/46
Filed: 1984-06-18
Abstract: Each process in a multi-process computing system using so-called capabilities may have associated with it a process dumpstack protected by the capability mechanism. The functions of this dumpstack are (i) to provide the state of the process at the point at which it was suspended and (ii) to stack (or nest) information relating to the invoked procedures (i.e. sub-routines) of the process. Thus there is a fixed sized portion containing principally the machine registers, the indicators and the watchdog timer values and a variable sized portion containing information related to each nested procedure. Each stack link is of fixed size and contains three items:- relativised instruction address, the code block capability and process capability pointer list block capability. This arrangement is enhanced to allowtwo additional classes of information to be stored in each link namely (a) an indication of the data and capability registers preserved during the domain change procedure and (b) descriptors for local storage segments. The use of descriptors for local storage allows a pool of storage particular to the process to be allocated on a segmented basis with the security of the capability mechanism extended into that local storage area. The descriptors for local storage segments resemble closely SCT entries (i.e. they contain sumcheck, base and limit values) and they are relative to a new protected stack, the local store stack, which is referenced by a hidden capability register C(L). The processor module is provided with a new instruction "subset local store" for use in local store segment allocation and automatic de-allocation occurs when a return is made from the procedure in which the local segment was allocated. Such allocation and de-allocation mechanisms use the indications which takes the form of a primary descriptor held in the most significant eight bits of the IAR word. This descriptor is allocated as follows:- (i) zero, no stacked registers or local segments allocated, (ii) m.s.b. = 1, stacked registers to be passed and (iii) I.s.b. 1-7 = 1, indicates the number of local store segments allocated. Associated with the stacked register set is a one word descriptor which indicates the registers stacked.
Patent IE-32616-L (IE)
Title: Wort concentrate or powder
IPC: C12C7/04
Filed: 1969-01-13
Abstract: 1,248,505. Producing wort concentrate or powder. CHEMISCHE FABRIEK NAARDEN N.V. Jan.17, 1969 [Jan. 19, 1968], No.2768/69. Heading C6E. A process for the manufacture of a brewers' wort in a concentrated or dried form comprises the steps of: (a) mixing a finely-divided starchcontaining material (barley, corn, rye, wheat, buckwheat or rice) with water at a temperature of from 30 to 50C. to form a mash having a solids content of from 25 to 50% by weight, (b) adding cellulose, hemicellulase, protease and α-amylase (optionally, pectinase also) to the mash and, if necessary, adjusting the pH of the mash to between 4 and 7, (c) raising the temperature of the mash to from 50 to 60C. so as to degrade and dissolve the cellulose, hemicellulose and proteins in the mash, (d) further raising the temperature of the mash to from 86 to 88C. so as to liquefy the starch constituents of the mash, (e) cooling the mash to from 55 to 62C., adding a saccharifying enzyme (malt flour, malt extract, fungal amylase or amyloglucosidase) and saccharifying the starch until the ratio of fermentable sugars to non-fermentable polysaccharides in the mash reaches a proportion suitable for the brewers' wort, (f) raising the temperature of the mash to from 85 to 115C. so as to inactivate the saccharifying enzymes, (g) filtering the mash, and (h) concentrating or drying the filtrate, after addition of hop extract (if desired).
[GB1248505A]
Patent IE-33039-L (IE)
Title: Anemia diagnosis composition
IPC: G01N33/82
Filed: 1969-01-24
Abstract: 1,219,884. Determination of methyl malonate. A. L. LUHBY. 31 Jan., 1969 [21 Feb., 1968], No. 5435/69. Heading B1X. [Also in Division A5] Methyl malonate in urine is determined by passing the urine sample first through a weakly basic anion exchange resin, then through a strongly acidic cation exchange resin, adjusting the effluent to pH 1.1. and mixing it with acetate buffer pH 4.3 and a solution of pnitroaniline in 0.2N HCl as diazo reagent. The colour developed is read at 620 mu.
[GB1219884A]
Patent IE-890160-L (IE)
Title: Process for the preparation of complex compounds
IPC: C07C259/06
Filed: 1989-01-19
Abstract: A process for the preparation of analytically pure chelate complexes which can be used in diagnostic medicine, for example as contrast agents or radiotherapeuticals, is described. In this process, a complex of a  beta -dicarbonyl compound and a metal ion, for example a metal acetylacetonate, which is readily soluble in an organic solvent which is not infinitely miscible with water, is recomplexed with a stoichiometric amount or a sub-equivalent amount of a chelating agent whose binding affinity to the metal ion is higher than that of the  beta -dicarbonyl compound.